

<!--row from index-->

<div class='container'>
    <div class='row row-header text-center'>
        <div class='col-12'>
            <h1>Pioneering Solutions to Medical Challenges</h1>
            <hr class='hr2'>
        </div>
    </div>

    <div class='row row-content'>
        <div class='col-12 col-sm-8'>
            <h3>Protection in Circulation for Safer Drug Delivery</h3>
            <p>Immunotherapy drugs en route to a tumor will either cause toxicity to other tissues or will be attacked by the body’s 
                immune system to prevent the drug from getting there. Vesselon drug delivery platform cloaks the drug to make sure it gets it to its intended destination.
            </p>
        </div>
        <div class='col-12 col-sm-8'>
            <h3>Affinity for Tumors</h3>
            <p>We target tumors without changing the drug. Others seek to add modifying agents to molecules to get new drugs to target tumors. This requires extensive, 
                iterative testing for activity and multiple clinical trials to prove safety and efficacy, resulting in significant capital investments over extended time 
                periods.
            </p>
        </div>
        <div class='col-12 col-sm-8'>
            <h3>Tumor Biodistribution</h3>
            <p>Once a systemic drug passes by a tumor, it doesn’t guarantee it gets INTO the tumor.  Vesselon’s technology enhances permeability and counters 
                interstitial pressure only at the tumor so that more drug gets into the tumor microenvironment to get the job done.
            </p>
        </div>
    </div>
</div>






<!--Text block from index-->



<div class='row row-content'>
    <div class='col-12 col-sm-8'>
        <h3>Protection in Circulation for Safer Drug Delivery</h3>
        <p>Immunotherapy drugs en route to a tumor will either cause toxicity to other tissues or will be attacked by the body’s 
            immune system to prevent the drug from getting there. Vesselon drug delivery platform cloaks the drug to make sure it gets it to its intended destination.
        </p>
    </div>
    <div class='col-12 col-sm-8'>
        <h3>Affinity for Tumors</h3>
        <p>We target tumors without changing the drug. Others seek to add modifying agents to molecules to get new drugs to target tumors. This requires extensive, 
            iterative testing for activity and multiple clinical trials to prove safety and efficacy, resulting in significant capital investments over extended time 
            periods.
        </p>
    </div>
    <div class='col-12 col-sm-8'>
        <h3>Tumor Biodistribution</h3>
        <p>Once a systemic drug passes by a tumor, it doesn’t guarantee it gets INTO the tumor.  Vesselon’s technology enhances permeability and counters 
            interstitial pressure only at the tumor so that more drug gets into the tumor microenvironment to get the job done.
        </p>
    </div>
</div>

<!--Problems/solutions from our tech-->

<div class='container'>
    <div class='row row-content align-items-center'>
        <div class='col-12 col-sm-8 offset-sm-2'>
            <h3 class='text-center'>Current Oncology Drugs Face Many Obstacles</h3>
            <p class='text-center'>Drugs aimed at combatting cancerous tumors run into problems
                in both circulation and at the tumoral area. Issues of toxicity, degredation, innefective Targeting,
                liver sequestration, and immunogenecity plague cancer drugs in the blood stream. When at the tumor,
                oftentimes not enough drug gets in, immune stimulation is too low, and immune suppresion too high.
            </p>
        </div>
        <div class='col-12'>
            <img src='img/problems.png' class='content-img graphics-img mobile-img'>
        </div>
    </div>

    <div class='row row-content align-items-center'>
        <div class='col-12 col-sm-8 offset-sm-2'>
            <h3 class='text-center'>Our Technology Bypasses These Roadblocks, Providing a More reliable
                and Efficient Means of Drug Delivery.
            </h3>
            <p class='text-center'>VEST™ technology protects the drug when in circulation, targets the tumoral area,
                penetration stromal barriers, increases the number of immune stimulating T cells,
                and decreases immune suppression.
            </p>
        </div>
        <div class='col-12'>
            <img src='img/solution.png' class='content-img graphics-img mobile-img'>
        </div>
    </div>
</div>

<!--Problems/Solutions Carousel-->

<div id="carouselExampleIndicators" class="carousel slide" data-ride="carousel" data-interval='10000' style='background-color: rgb(162, 162, 162, 0.3);'>
    <ol class="carousel-indicators" style="margin-top: 25px;">
      <li data-target="#carouselExampleIndicators" data-slide-to="0" class="active"></li>
      <li data-target="#carouselExampleIndicators" data-slide-to="1"></li>
    </ol>
    <div class="carousel-inner" style='border-bottom: none;'>
      <div class="carousel-item active">
        <h3 class='text-center' style='margin: 1em 0;'>Current Oncology Drugs Face Many Obstacles</h3>
        <img class="d-block w-45" src="img/problem.png" alt="First slide" style="margin: 25px auto;">
      </div>
      <div class="carousel-item">
        <h3 class='text-center' style='margin: 1em 0;'>Our Technology Bypasses These Roadblocks, Providing a More Reliable
            and Efficient Means of Drug Delivery.
        </h3>
        <img class="d-block w-45" src='img/solution.png' alt="Second slide" style="margin: 25px auto;">
      </div>

    </div>
    <a class="carousel-control-prev" href="#carouselExampleIndicators" role="button" data-slide="prev">
      <span class="carousel-control-prev-icon" aria-hidden="true"></span>
      <span class="sr-only">Previous</span>
    </a>
    <a class="carousel-control-next" href="#carouselExampleIndicators" role="button" data-slide="next">
      <span class="carousel-control-next-icon" aria-hidden="true"></span>
      <span class="sr-only">Next</span>
    </a>
</div>


<!--
    Vid from tech page
-->

<div class='vidContent'>
    <video autoplay muted loop >
        <source src='movies/newVesselEdit.mp4' type="video/mp4">
    </video>
    <div class='overlay'>
        <h1 class='text-center'>Our Drugs Are Breaking The Oncology Sound Barrier</h1>
        <hr>
        <p class='boxText'>We solve the biggest problems facing many Oncology
            drugs: toxicity, degradation, and limited immune response.
        </p>
    </div>
</div>






<!--Drugs we can conjugate and vessel from clinical areas-->

<div class='col-12'>
    <div class='col-12'>
        <h3 class='text-center'>Drugs We Can Conjugate</h3>
    </div>
    <div class='col-12'>
        <img src='img/drugsInVessel.png' class='content-img mobile-img'>
    </div>
</div>


<!--Vertical layout style from about us page-->

<div class="row row-content">

    <div class='col-12'>
        <h2 class='name-text'>Clayton T. Larsen</h2>
    </div>
    <div class='col-12'><p class='title-text'>Co-Founder, President, and CEO</p></div>
    <div class='col-12 col-sm-3'>
        <img src='img/clay.png' class='img-face'>
    </div>

    <div class='col-12 col-sm-8 offset-sm-1'>
        <p class='description-text'>Mr. Larsen co-founded Vesselon in 2012 and brings over thirty years 
            of executive management, marketing, sales, clinical innovation and engineering/project management 
            in the healthcare industry. Mr. Larsen was a senior executive with FUJIFILM Medical Systems, 
            where he was largely responsible for building the company’s first healthcare software division 
            from the ground up.  Mr. Larsen recruited the original senior architects and was instrumental 
            in the development, marketing, commercial release and field support of Fuji's Synapse® Picture 
            Archive and Communication System (PACS).
            <br>
            
            In a move to Silicon Valley in 1988, Mr. Larsen served 
            in several senior roles at Acuson Corporation culminating as Vice President of New Market 
            Development. Acuson was one of the leading ultrasound technology companies that was later 
            acquired by Siemens.  Early in his career he specialized in Sales and Marketing Management 
            of Ultrasound and Nuclear Medicine for Picker International.  Mr. Larsen holds a B.S. 
            in Molecular Biophysics and Biochemistry from Yale University.
        </p>  
    </div>

</div>

<div class="row row-content">

    <div class='col-12'>
        <h2 class='name-text'>Rhodemann Li</h2>
    </div>
    <div class='col-12'><p class='title-text'>Executive VP and Strategy</p></div>
    <div class='col-12 col-sm-3'>
        <img src='img/Rhodemann.png' class='img-face'>
    </div>

    <div class='col-12 col-sm-8 offset-sm-1'>
        <p class='description-text'>Mr. Li is the founder of Vesselon and is a serial healthcare entrepreneur. 
            He brings more than thirty years of experience in finance, business development, strategy, patents 
            and regulatory submissions. Mr. Li continues to direct the company's strategy and has secured 
            multiple assets and licenses to key patents for the combination of therapeutics utilizing the 
            company's platform technology. 
            <br>
            <br>
            Prior to founding Vesselon, Mr. Li worked in both healthcare 
            private equity and investment banking.  Mr. Li co-founded an orthopedic implant company, 
            Li Medical Technologies, which developed and sold sports medicine and spinal implants. 
            Li Medical was venture capital funded and was acquired by Conmed Corporation. Mr. Li has 
            five issued patents and additional pending patents
        </p>  
    </div>

</div>

<div class="row row-content">

    <div class='col-12'>
        <h2 class='name-text'>Neil Edwards</h2>
    </div>
    <div class='col-12'><p class='title-text'>Chief Financial Officer</p></div>
    <div class='col-12 col-sm-3'>
        <img src='img/neil.png' class='img-face'>
    </div>

    <div class='col-12 col-sm-8 offset-sm-1'>
        <p class='description-text'>Neil Edwards joined Vesselon as CFO in December 2019 bringing 30 years of 
            business execution strategy and fund-raising experience to the team.  Edwards served in C-suite 
            roles in Interos, VeriSign, infoGroup, and dotMobi over his career.  As CEO of dotMobi, he secured 
            investments from Google, Vodaphone, Visa, and Samsung.  As CRO at Interos.ai, he led the Kleiner 
            Perkins funding and acquisition of Trensant.  Edwards is a regular contributor with Forbes and 
            sits on several boards.  He holds a B.A. in Mathematics & Computer Science from The Citadel, and 
            completed graduate work at Duke University.
        </p>  
    </div>

</div>

<div class='row' style='margin-top: 3em;'>
    
    <h2 class='management-text'>Board of Directors</h2>
    
</div>


<div class="row row-content">

    <div class='col-12'>
        <h2 class='name-text'>Llew Keltner, MD, PHD</h2>
    </div>
    <div class='col-12'><p class='title-text'>Director</p></div>
    <div class='col-12 col-sm-3'>
        <img src='img/llew.png' class='img-face'>
    </div>

    <div class='col-12 col-sm-8 offset-sm-1'>
        <p class='description-text'>Llew Keltner, M.D., Ph.D., has a 40-year career in biopharma drug and business development. He is Chief Executive Officer of EPISTAT, an international healthcare technology transfer, corporate risk management and healthcare strategy company that he founded in 1972. Dr. Keltner was the Chief Executive Officer of AgonOx, a biotech company developing OX40 agonists for use in cancer therapy, from 2011 to 2013. He was the President of Novici Biotech, a privately-held gene and protein optimization firm in 2010 and 2011.

 

            Dr. Keltner was Chief Executive Officer and President of Light Sciences Oncology, a privately-held biotechnology company developing a late stage, light-activated therapy for hepatocellular cancer and other solid tumors from 2001 to 2010. From 1997 to 2004, Dr. Keltner was Chief Executive Officer of Metastat, a development-stage biotech company focused on cancer metastasis.
            
            ​
            
            Dr. Keltner holds positions on the boards of Curetech, Infostat, BioQ Pharma, Oregon Life Sciences, Surgeon Training International, OncoSCAR, and Goodwell Technologies. He is a previous Director of Raptor Pharmaceuticals, where he served as Chairman (NASDAQ:RPTP), Light Sciences Corporation, Immunovaccine (TSX.V:IMV),Vital Choice, Thesis Technologies, Oread Companies, and MannKind Corporation (NASDAQ:MNKD). He has also been a scientific advisory board member at Heat Biologics, Pelican Therapeutics, Lifetime Corporation, ASB Meditest, Oread Laboratories, Hall-Kimbrell, and aai Pharma.
            
             
            
            Dr. Keltner is an Associate Professor at Case Western Reserve School of Medicine, and a Guest Lecturer and Director in the Bioethics Program at Columbia University School of Medicine. He is currently a member of the American Society of Clinical Oncology, American Association of Cancer Research, American Medical Association, International Association of Tumor Marker Oncology, American Association of Clinical Chemistry, and Drug Information Association. Dr. Keltner received an M.S. in Epidemiology and Biostatistics, a Ph.D. in Biomedical Informatics and an M.D. from Case Western Reserve University in Cleveland, Ohio. Dr. Keltner has also authored many research publications.
        </p>  
    </div>

</div>

<div class="row row-content">

    <div class='col-12'>
        <h2 class='name-text'>Adam Levy, PHD, MBA</h2>
    </div>
    <div class='col-12'><p class='title-text'>Director</p></div>
    <div class='col-12 col-sm-3'>
        <img src='img/adam.jpeg' class='img-face'>
    </div>

    <div class='col-12 col-sm-8 offset-sm-1'>
        <p class='description-text'>Adam Levy, PhD, MBA, is  currently EVP, Investor Relations and Corporate Communications at Ziopharm Oncology. Prior to this role, Dr. Levy was Executive Director and Head, Corporate Strategy and Investor Relations for Gilead Sciences. Previously, Dr. Levy was VP, Corporate Strategy for Alexion and Executive Director, Corporate Strategy for Bristol-Myers Squibb. He also has held prior leadership positions with Novartis and served as a consultant at McKinsey & Company. Adam holds a B.S. in Genetics and a Ph.D. in Molecular Biology, both from the University of Illinois and an MBA in Finance and Strategy from Northwestern University Kellogg School of Management.
        </p>  
    </div>

</div>

<div class="row row-content">

    <div class='col-12'>
        <h2 class='name-text'>Steve Mahoney</h2>
    </div>
    <div class='col-12'><p class='title-text'>Director</p></div>
    <div class='col-12 col-sm-3'>
        <img src='img/steve.png' class='img-face'>
    </div>

    <div class='col-12 col-sm-8 offset-sm-1'>
        <p class='description-text'>Steve Mahoney has over 20 years of biotechnology and health care industry experience.  He is currently the Chief Financial and Operating Officer of Magenta Therapeutics, Inc. focused on improving stem cell transplantation across a variety of diseases areas, including hematology oncology.  He was previously President and Chief Operating Officer of Kiniksa Pharmaceuticals which acquired/in-licensed multiple product candidates at different stages of clinical development for further advancement.  Prior to this role, Steve was the Chief Commercial Officer of Synageva Biopharma prior to its acquisition by Alexion Pharmaceuticals and previously held various roles over a 10 year tenure at Genzyme Corporation.  Steve holds an MBA and JD from Boston College and a BA from Colorado College. 
        </p>  
    </div>

</div>
